Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
thalidomide + interferon
- Development stage
- Phase 2
- Lead developer
- Grünenthal
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Oral, Subcutaneous, Intramuscular
01
Overview
Thalidomide + interferon is a combination therapy consisting of thalidomide, an oral immunomodulatory and anti-angiogenic small molecule, and interferon (typically recombinant human interferon-alpha), a cytokine with antiviral, antiproliferative, and immunomodulatory properties. Thalidomide acts by modulating the immune system, inhibiting tumor necrosis factor-alpha (TNF-α) production, and suppressing angiogenesis. Interferons bind to cell surface receptors to activate intracellular signaling pathways that enhance immune responses against malignant cells. This combination has been investigated for the treatment of recurrent or refractory hematologic malignancies such as acute myeloid leukemia (AML) and multiple myeloma. The rationale for combining these agents is their complementary mechanisms—thalidomide’s immunomodulation/anti-angiogenesis with interferon's direct stimulation of antitumor immunity[3][4][7].
- Other names
- thalidomide + alpha interferonthalidomide + interferon alphathalidomide combined with interferons
02
Targets
CRBN (Cereblon)IFNAR (Immune system modulation via type I interferon receptor)IFNAR2 (Interferon alpha/beta receptor subunit 2)IKZF1 (Ikaros family zinc finger protein 1)IKZF3 (Zinc finger protein Aiolos)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on thalidomide + interferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on thalidomide + interferon.